Search bioRxiv⌕ Search

Biology subjects

Qin, H.

Publications and source records attributed to Qin, H..

At least 37 records · Page 2Linked to original sources

Physics-Diffusion-Driven Multiscale Aggregation for Drug-Target Interaction Prediction

Drug-target interaction prediction is an important task in computational drug discovery. To address the limitations of existing graph neural network approaches in propagation depth and robustness, we propose PDDMA-DTI (Physics-Diffusion-Driven Multiscale Aggregation for Drug-Target Interaction Prediction), a physics-inspired, multiscale adaptive aggregation framework. PDDMA-DTI injects a physics-motivated diffusion operator into a heterogeneous drug-target network: global diffusion models cross-modal information propagation via the graph Laplacian, while local diffusion performs neighborhood smoothing in the low-dimensional embedding space. Both processes are solved with the implicit Euler scheme to ensure numerical stability. For each node, we introduce an adaptive stopping rule based on steady-state convergence and a weighted fusion strategy. This strategy leverages hop counts and node degrees to aggregate multi-step diffusion snapshots into a final representation that preserves original features while capturing multi-scale context. To emphasize strong interaction pathways, we further propose a Physical Interaction Summation Enhancement module that augments pairwise interaction features with a linear plus quadratic energy term, thereby amplifying highly correlated drug-target pairs. Extensive experiments on multiple benchmark datasets show that PDDMA-DTI consistently outperforms representative baselines in accuracy and robustness.

bioinformatics↗

Xanthomonas type III effector XopN targets scaffold protein OsRACK1B to suppress rice immunity

Bacterial leaf streak (BLS), caused by Xanthomonas oryzae pv. oryzicola (Xoc), is a major bacterial disease that poses a substantial threat to rice production. Although Xoc deploys a variety of effectors to subvert host defenses, the mechanistic basis of how these effectors modulate plant immune signaling remains largely unclear. Here, we show that XopN suppresses rice immune responses and physically interacts with the rice scaffold protein OsRACK1B. Notably, OsRACK1B expression is induced following Xoc infection in a type III secretion system (T3SS)-independent manner. Functional analyses indicate that OsRACK1B overexpression enhances Xoc resistance, whereas loss-of-function mutants exhibit heightened susceptibility. This increased susceptibility is characterized by compromised immunity, including reduced callose deposition, diminished reactive oxygen species (ROS) accumulation, and attenuated expression of defense-related genes such as OsPBZ1 and OsPAL1. Furthermore, we demonstrate that XopN competes with OsRap2.6 for binding to OsRACK1B, thereby disrupting the formation of the OsRACK1B-OsRap2.6 immune complex. These findings reveal a novel virulence strategy in Xoc and identify promising gene targets for developing disease-resistant rice varieties.

plant biology↗

Activated protein C promotes beta-arrestin-2- and c-Src-dependent caveolin-1 (Cav1) phosphorylation and alters Cav1 association with PAR1 and GRK5

G protein-coupled receptors (GPCRs) display bias towards either G proteins or GPCR kinase (GRK)-mediated {beta}-arrestin signaling depending on the agonist stabilized receptor conformation and cellular context. The cellular location of GPCRs particularly within plasma membrane microdomains such as lipid rafts contributes to biased signaling through mechanisms that are not well understood. The protease-activated receptor-1 (PAR1) exhibits biased signaling in response to thrombin and activated protein C (APC). APC-induced {beta}-arrestin-2 ({beta}arr2) biased signaling requires PAR1 compartmentalization in caveolae, a subtype of lipid rafts, whereas thrombin-activated PAR1 G protein signaling does not. Caveolin-1 (Cav1) is the principal structural protein of caveolae and regulates signaling through protein-protein interactions. The mechanisms by which Cav1 contributes to APC/PAR1-induced {beta}arr2 biased signaling is not known. Here we report that APC-activated PAR1 modulates Cav1 phosphorylation via a {beta}arr2- and c-Src-dependent pathway. APC also regulates the dynamics of endogenous PAR1-Cav1 and GRK5-Cav1 co-localization examined by single molecule super-resolution stochastic optical reconstruction microscopy imaging in human cultured endothelial cells. We further demonstrate that GRK5 interacts with Cav1 in intact cells through an N-terminus aromatic-rich consensus Cav1 binding motif. Unlike wildtype GRK5, a GRK5 mutant defective in Cav1 binding localized predominantly to the cytoplasm rather than the plasma membrane and failed to promote {beta}arr2 recruitment to APC-activated PAR1. These studies suggest that Cav1 itself contributes to the regulation of APC-activated PAR1 {beta}arr2 biased signaling likely through multiple mechanisms that may converge on GRK5.

cell biology↗

Signaling bias of the protease-activated receptor-1 is dictated by distinct GRK5 and β-arrestin-2 determinants

G protein-coupled receptors (GPCRs) exhibit signaling bias, or preferential activation of heterotrimeric G proteins versus GPCR receptor kinase (GRK)-mediated {beta}-arrestin signaling. The protease-activated receptor-1 (PAR1) GPCR activates both G protein and {beta}-arrestin in response to thrombin, but only {beta}-arrestin in response to activated protein C (APC). Thrombin-activated PAR1-G protein signaling is desensitized by {beta}-arrestin-1, whereas APC-activated PAR1 signaling is propagated by {beta}-arrestin-2. The mechanisms underlying PAR1 biased signaling are not known. Here, using computational modeling and cell biology studies, we reveal the molecular basis of signaling by thrombin- and APC-activated PAR1. Although both thrombin- and APC-induced PAR1 signaling are regulated by the same GRK isoform, GRK5, the two types of signaling are differentially dependent on GRK5 membrane anchoring, PAR1 C-terminal phosphorylation, and the binding mode of {beta}-arrestin-2. These differences translate into distinct {beta}-arrestin-2 conformations and define the cytoprotective signaling signature by APC which contrasts with thrombin inflammatory signaling.

cell biology↗

Microbiome-Dependent Functional Responses to Structurally Distinct Oligosaccharides Revealed by Metaproteomics

Dietary oligosaccharides are prebiotics that fuel gut microbes, but individual microbiomes may respond differently depending on oligosaccharide structures as well as microbiome composition and function. The extent to which specific gut microbial communities exhibit personalized functional responses to distinct oligosaccharides remains underexplored. We applied a standardized ex vivo microbiome culture, called RapidAIM, coupled with metaproteomics to examine how six structurally diverse oligosaccharides affect the gut microbiota functional response. Our study shows that while human gut microbiomes share some commonalities in utilizing oligosaccharides (e.g. prioritizing dietary fibers over mucin), the fine-scale metabolic and taxonomic responses are highly individualized. Such findings underscore the importance of considering personal microbiome profiles when predicting the outcome of prebiotic interventions. In a broader context, our metaproteomic approach provides a framework for identifying optimal prebiotic choices tailored to individual microbiomes. Ultimately, understanding these personalized responses could inform precision nutrition strategies.

microbiology↗

UniCell: Towards a Unified Solution for Cell Annotation, Nomenclature Harmonization, Atlas Construction in Single-Cell Transcriptomics

Standardizing cell type annotations across single-cell RNA-seq datasets remains a major challenge due to inconsistencies in nomenclature, variation in annotation granularity, and the presence of rare or previously unseen populations. We present UniCell, a hierarchical annotation framework that combines Cell Ontology structure with transcriptomic data for scalable, interpretable, and ontology-aware cell identity inference. UniCell leverages a multi-task architecture that jointly optimizes local and global classifiers, yielding coherent predictions across multiple levels of the ontology-defined hierarchy. When benchmarked across 20 human and mouse datasets, UniCell consistently outperformed state-of-the-art tools, including CellTypist, scANVI, OnClass, and SingleR, in annotation performance, and sensitivity to low-abundance populations. In disease settings, UniCell effectively identified previously unseen cell types through confidence-guided novelty detection. Applied to 45 human and 23 mouse tissue atlases, UniCell enabled cross-dataset and cross-species harmonization by embedding cells into a unified latent space aligned with Cell Ontology structure. Moreover, when used to supervise single-cell foundation models, UniCell substantially improved downstream annotation accuracy, rare cell detection, and hierarchical consistency. Together, these results establish UniCell as a generalizable framework that supports high-resolution annotation, nomenclature standardization, and atlas-level integration, providing a scalable and biologically grounded solution for single-cell transcriptomic analysis across diverse biological systems.

bioinformatics↗

The 1000+ mouse project: large-scale spatiotemporal parametrization and modeling of preclinical cancer immunotherapies

Preclinical studies of chimeric antigen receptor (CAR)-T cell immunotherapies are often based on monitoring bioluminescent tumors implanted in mice to assess anti-tumor cytotoxicity. Here, we introduce maRQup (murine automatic Radiance Quantification and parametrization), an easy-to-use method that automatically processes bioluminescent tumor images for quantitative analysis. We demonstrate the ability of maRQup to analyze CAR-T cell treatments over >1,000 tumor-bearing mice. We compare CD19-targeting CAR-T cells comprising either a CD28 or a 4-1BB costimulatory domain, and found the former controlled the tumor burden better initially, while the latter reduced the frequency of tumor relapse. We also applied maRQup to demonstrate faster tumor growth during the initial growth phase as compared to the relapse phase and to spatiotemporally analyze the high variability in immunotherapeutic control of tumors, based on their anatomical location. maRQup provides quantitative and statistically-robust insights on preclinical experiments that will contribute to the optimization of immunotherapies.

immunology↗

STAT3 Sustains Tumorigenicity Following Mutant KRAS Ablation

Oncogenic KRAS mutations underlie some of the deadliest human cancers. Genetic or pharmacological inactivation of mutant KRAS is not sufficient for long-term control of advanced tumors. Using a conceptual framework of pancreatic ductal adenocarcinoma, we find that CRISPR-mediated ablation of mutant KRAS can terminate tumor progression contingent on the concomitant inactivation of STAT3. STAT3 inactivation is needed to ensure that KRAS-ablated tumor cells lose their malignant identity. Mechanistically, the combined loss of mutant KRAS and STAT3 disrupts a core transcriptional program of cancer cells critical to oncogenic competence. This in turn impairs tumor growth in mice and enhances immune rejection, leading to tumor clearance. We propose that the STAT3 transcriptional program operating in cancer cells enforces their malignant identity, rather than providing classical features of transformation, and shapes cancer persistence following KRAS inactivation. Our findings establish STAT3 as a critical enforcer of oncogenic identity in KRAS-ablated tumors, revealing a key vulnerability that could be exploited for combination therapies. SignificanceThe limited clinical success of KRAS inhibitors points to the need to identify means by which tumor cells maintain stemness and immune evasion. We make an unprecedented finding that the STAT3 transcription factor can sustain tumorigenicity of pancreatic cancer cells following depletion of the KRAS oncogenic driver. The results have important implications for successful therapeutic intervention.

cancer biology↗

The circulating cell-free DNA landscape in sepsis is dominated by impaired liver clearance

Circulating cell-free DNA (cfDNA) is a promising molecular biomarker. However, its utility in severe infection remains poorly understood. Here, we isolated cfDNA from sepsis patients and controls, demonstrating a 41-fold increase in the amount of cfDNA in circulation during disease. We used sequencing to reconstruct cfDNA methylomes, fragmentation profiles, and nucleosome footprints across 56 samples. We observed no difference in cfDNA composition between patients and controls, challenging the idea that cfDNA increases due to higher immune cell death during sepsis. Instead, we suggest that liver dysfunction prevents efficient clearance of cfDNA during disease. This was supported by fragmentation and end-motif patterns, both of which showed evidence of cfDNA being exposed to circulating nucleases for a prolonged period, proportionally to the extent of liver dysfunction. Variation in cfDNA of megakaryocyte-erythroid progenitor origin was also a significant contributor in sepsis, increasing over time. Moreover, we showed that cfDNA retains nucleosome footprints with cell type-specific gene activity information. We developed a novel approach to study nucleosome phasing that successfully recovers tissue-specific signatures. By combining this with single-cell data, we demonstrated that sepsis patients with liver dysfunction have higher amounts of cfDNA derived from Kupffer cells and the liver parenchyma. In conclusion, we present the first high-throughput multi-modal study of cfDNA during sepsis, which will serve as a reference point for future studies on the role of this biomarker in critical illness.

genomics↗

Systematic Metaproteomics Mapping Reveals Functional and Ecological Landscapes of Human Gut Microbiota Responses to Therapeutic Drugs

Therapeutic compounds exert impacts on gut microbiota; however, how they affect the community functional ecology, especially as reflected at the protein level, remains largely unexplored. In this study, we systematically map metaproteomic responses of ex vivo human gut microbiota to 312 compounds, generating 4.6 million microbial protein responses, available as an interactive resource (https://shiny.imetalab.ca/MPR_Viz/). Protein-level analyses identify significant metaproteomic shifts induced by 47 compounds, with neuropharmaceuticals as the sole drug class significantly enriched among these hits. Further analyses on the community level reveal a tri-stability pattern in microbial composition and the emergence of three distinct functional states, based on a functional beta-diversity metric. Notably, neuropharmaceuticals cause particularly strong effects on the microbiomes, lowering the proteome-level functional redundancy and raising the level of antimicrobial resistance proteins, ultimately pushing the microbiome into an alternative functional state. Preliminary validation suggests that enhancing functional redundancy may contribute to maintaining microbiota resilience against neuropharmaceutical-induced antimicrobial resistance. Overall, this work establishes a comprehensive view of how drugs influence gut microbiome function and ecology at the protein level, proposes a landscape-based framework for interpreting community resilience, and highlights the need to consider protein-level and ecological responses in the evaluation of therapeutic interventions.

microbiology↗

RegFormer: A Single-Cell Foundation Model Powered by Gene Regulatory Hierarchies

Single-cell RNA sequencing (scRNA-seq) enables high-resolution profiling of cellular diversity, but current computational models often fail to incorporate regulatory priors, handle data sparsity, or efficiently process long gene sequences. Here, we present RegFormer, a foundation model that integrates gene regulatory networks (GRNs) with Mamba-based state-space modeling, overcoming the scalability and context-length limitations of Transformer architectures. RegFormer encodes each gene through dual embeddings, a value embedding for quantitative expression and a token embedding for regulatory identity, organized within a GRN-guided gene order to capture both expression dynamics and hierarchical regulation. Pretrained on 26 million human single cells spanning 45 tissues and diverse biological contexts, RegFormer achieves superior scalability and biological fidelity. Across comprehensive benchmarks, it consistently outperforms state-of-the-art single-cell foundation models (scGPT, Geneformer, scFoundation, and scBERT), delivering higher clustering accuracy, improved batch integration, and more precise cell type annotation. RegFormer also reconstructs biologically coherent GRNs, accurately models transcriptional responses to genetic perturbations, and enhances drug response prediction across cancer cell lines. By combining regulatory priors with efficient long-sequence Mamba modeling, RegFormer establishes a biologically grounded and scalable framework for single-cell representation learning, enabling deeper mechanistic insight into gene regulation and cellular state transitions.

bioinformatics↗

Mycobacterium tuberculosis CrgA Forms a Dimeric Structure with Its Transmembrane Domain Sandwiched between Cytoplasmic and Periplasmic β-Sheets, Enabling Multiple Interactions with Other Divisome Proteins

CrgA is a key transmembrane (TM) protein in the cell division process of Mycobacterium tuberculosis (Mtb), the pathogen responsible for tuberculosis. While many of the Mtb divisome proteins have been identified, their structures and interactions remain largely unknown. Previous studies of CrgA using oriented-sample solid-state NMR have defined the tilt and rotation of the TM helices, but the cytoplasmic and periplasmic domains and even the oligomeric state were uncharacterized. Here, combining oriented-sample and magic-angle spinning solid-state NMR spectra, we solved the full-length structure of CrgA. The structure features a dimer with a TM domain sandwiched between a cytoplasmic {beta}-sheet and a periplasmic {beta}-sheet. The {beta}-sheets stabilize dimerization, which in turn increases CrgAs ability to participate in multiple protein interactions. Within the membrane, CrgA binds FtsQ, CwsA, PbpA, FtsI, and MmPL3 via its TM helices; in the cytoplasm, Lys23 and Lys25 project outward from the {beta}-sheet to interact with acidic residues of FtsQ and FtsZ. The structural determination of CrgA thus provides significant insights into its roles in recruiting other divisome proteins and stabilizing their complexes for Mtb cell wall synthesis and polar growth.

biophysics↗

Single CAR-Dual target: Intracranial Delivery of Anti-PD-L1 CAR T Cells Effectively Eradicates Glioma and Immunosuppressive Cells in the Tumor Microenvironment.

With the goal to overcome the limited treatment options and poor prognosis of glioblastoma (GBM), we have developed a PD-L1-targeting CAR T cell therapy, MC9999. In vitro experiments with MC9999 CAR T cells derived from GBM patients exhibited potent, antigen-specific cytotoxicity against autologous tumor cells and immunosuppressive cells within the tumor microenvironment (TME). In an orthotopic GBM model using patient-derived brain tumor-initiating cells, the intracranial delivery of MC9999 CAR T cells eradicated established tumors and improved survival. Single-cell RNA sequencing indicated that MC9999 CAR T cells activate interferon pathways, leading to GBM cell apoptosis. Multi-immunohistochemistry confirmed localized PD-L1 expression on tumor cells and TME-residing macrophages, but not in neurons or glia in patient tissue. The local delivery of MC9999 CAR T cells may be a safe, effective approach for simultaneously targeting PD-L1-positive GBM and its immunosuppressive TME and a strategy to overcome immune evasion and enhance the therapeutic potency of CAR T cell therapy against GBM.

cancer biology↗

BioLLM: A Standardized Framework for Integrating and Benchmarking Single-Cell Foundation Models

The application and evaluation of single cell foundational models (scFMs) present significant challenges stemming from the heterogeneity of architectural frameworks and coding standards. To address these issues, we introduce BioLLM, a framework facilitating the integration and application of scFMs in single-cell RNA sequencing data analysis. BioLLM provides a universal interface, bridging diverse scFMs into a seamless ecosystem. By mitigating architectural disparities and coding conventions, it empowers researchers with streamlined access to scFMs. With standardized APIs and comprehensive documentation, BioLLM streamlines model switching and comparative analyses, while incorporating best practices for consistent model evaluation. Our comprehensive evaluation of scFMs revealed distinct strengths and limitations, highlighting scGPTs robust performance across all tasks, both in zero-shot and fine-tuning scenarios. Geneformer and scFoundation also demonstrated strong capabilities in gene-level tasks, benefiting from effective pretraining strategies. In contrast, scBERT underperformed relative to other models, likely attributable to its considerably smaller parameter count and the limited size of the training dataset. Ultimately, BioLLM aims to empower the scientific community to leverage the full potential of foundational models, advancing our understanding of complex biological systems through enhanced single-cell analysis.

bioinformatics↗

The E3 ligase NEDD4L prevents colorectal cancer liver metastasis via degradation of PRMT5 to inhibit the AKT/mTOR signaling pathway

Colorectal cancer is the second most common cause of cancer mortality worldwide, and liver metastasis is the major cause of death in patients with colorectal cancer. Dysfunctional E3 ligase activity has recently been shown to be associated with colorectal cancer. However, the key E3 ligase affecting colorectal cancer liver metastasis remains unknown. Therefore, we used an shRNA library targeting 156 E3 ubiquitin ligases to perform an in vivo loss-of-function screen of a human colorectal cancer cell line in a mouse model of colorectal cancer liver metastasis. The screen revealed that NEDD4L knockdown promoted colorectal cancer liver metastasis. Moreover, overexpression of NEDD4L prevented colorectal cancer liver metastasis. Mechanistic studies revealed that NEDD4L bound to the PPNAY motif in PRMT5 and ubiquitinated PRMT5 to promote its degradation. PRMT5 degradation attenuated the methylation of an arginine residue in AKT1 to inhibit the AKT/mTOR signaling pathway, consequently decreasing colorectal cancer cell proliferation. We are the first to show that PRMT5 is a substrate protein of the E3 ligase NEDD4L and reveals not only the metastasis-inhibiting function of NEDD4L but also a novel mechanism by which NEDD4L suppresses colorectal cancer liver metastasis. These findings may provide a new preventive strategy for liver metastasis.

cancer biology↗

Brainstem neurons coordinate the bladder and urethra sphincter for urination

Urination, a vital and conserved process of emptying urine from the urinary bladder in mammals, requires precise coordination between the bladder and external urethral sphincter (EUS) that is tightly controlled by a complex neural network. However, the specific subpopulation of neurons that accounts for such coordination remains unidentified, limiting the development of target-specific therapies for certain urination disorders, e.g., detrusor-sphincter dyssynergia. Here, we find that cells expressing estrogen receptor 1 (ESR1+) in the pontine micturition center (PMC) initiate voiding when activated and suspend ongoing voiding when suppressed, each at 100% reliability. Transection of the pelvic nerve does not impair PMCESR1+ neurons control of the EUS via the pudendal nerve, whereas transection of the pudendal nerve does not impair their control of the bladder via the pelvic nerve. Anatomically, PMCESR1+ neurons consist of three distinct spinal-projection-based subpopulations: one targeting the sacral parasympathetic nucleus (SPN), one innervating the dorsal gray commissure (DGC), and a third that projects to both regions, thereby enforcing the coordination of bladder contraction and sphincter relaxation in a rigid temporal sequence. Thus, we identify a cell type in the brainstem that controls the bladder-urethra coordination for urination.

neuroscience↗

Integrated Analysis of Single-Cell and Bulk RNA-Seq Data reveals that Ferroptosis-Related Genes Mediated the Tumor Microenvironment predicts Prognosis, and guides Drug Selection in Triple-Negative Breast Cancer

BackgroundTriple-negative breast cancer (TNBC) is aggressive, lacking methods to predict recurrence and drug sensitivity. Ferroptotic heterogeneity varies in TNBC subtypes. However, the tumor microenvironment (TME) mediated by ferroptosis genes is unclear. Our study aims to integrate single-cell and bulk RNA sequencing (RNA-seq) data to reveal the ferroptosis-mediated TME in TNBC, predicting prognosis and guiding treatment. MethodsThe single-cell and bulk RNA-seq data of TNBC were sourced from the Gene Expression Omnibus (GEO) database. Using these data, a machine learning algorithm was employed to integrate and analyze the characteristics of the TME mediated by ferroptosis-related genes in TNBC. Prediction models for TNBC survival prognosis and drug treatment response were established and then validated in an independent set. ResultsAt the individual cell level, T cells were categorized into three distinct subpopulations, and local macrophages into two subpopulations. The infiltration degree of these different cell subpopulations was closely associated with prognosis and treatment outcomes. Based on this, the risk score model we developed effectively predicted recurrence-free survival in TNBC patients, with independently validated pooled predicted 3-, 4-, and 5-year Area Under the Curves (AUCs) of 0.65, 0.67, and 0.71, respectively. Additionally, we found that patients in the high-risk group may be more responsive to 27 drugs. ConclusionsWe have uncovered the tumor immune cell clusters in TNBC mediated by ferroptosis. A risk score model was constructed to identify high-risk TNBC patients, which can assist physicians in disease monitoring and precision therapy. The genes identified hold significant potential as therapeutic targets for TNBC patients. FundingThis project is funded by the National Natural Science Foundation of China (81974268, 82472000, 82304151), the Talent Incentive Program of Cancer Hospital Chinese, Academy of Medical Sciences (801032247), the Cooperation Fund of CHCAMS (CFA202202023), and the open project of Beijing Key Laboratory of Tumor Invasion and Metastasis Mechanism, Capital Medical University(2023ZLKF03). Impact StatementIntegrating single-cell and bulk RNA-seq data elucidates the role of ferroptosis in TNBC, offering a prognostic model and personalized therapeutic insights.

cancer biology↗

Advancing CAR T-Cell Therapy: Simultaneously Attack Tumor and Immunosuppressive Cells in the Tumor Microenvironment

Chimeric antigen receptor (CAR) T-cell therapy has encountered limited success in solid tumors. The lack of dependable antigens and the immunosuppressive tumor microenvironment (TME) are major challenges. Within the TME, tumor cells along with immunosuppressive cells employ an immune-evasion mechanism that upregulates programmed death ligand 1 (PD-L1) to deactivate effector T cells; this makes PD-L1 a reliable, universal target for solid tumors. We developed a novel PD-L1 CAR (MC9999) using our humanized anti-PD-L1 monoclonal antibody, designed to simultaneously target tumor and immunosuppressive cells. The antigen-specific antitumor effects of MC9999 CAR T-cells were observed consistently across four solid tumor models: breast cancer, lung cancer, melanoma, and glioblastoma multiforme (GBM). Notably, intravenous administration of MC9999 CAR T-cells eradicated intracranially established LN229 GBM tumors, suggesting penetration of the blood-brain barrier. The proof-of-concept data demonstrate the cytolytic effect of MC9999 CAR T-cells against immunosuppressive cells, including microglia HMC3 cells and M2 macrophages. Furthermore, MC9999 CAR T-cells elicited cytotoxicity against primary tumor-associated macrophages within GBM tumors. The concept of targeting both tumor and immunosuppressive cells with MC9999 was further validated using CAR T-cells derived from cancer patients. These findings establish MC9999 as a foundation for the development of effective CAR T-cell therapies against solid tumors.

cancer biology↗